New Delhi: Two corona vaccines in India have been allowed to be used in emergencies. These are covishield and Covaxin. Out of these, Covaxin has been prepared by Bharat Boytech and it is a completely indigenous vaccine, but people across the country are afraid of taking this vaccine. Health workers are also questioning the impact of this vaccine. However, there is now good news about this vaccine made in India. The results of the first phase of Covaxin have been published in the famous medical journal The Lancet, according to which, this vaccine has increased the immune response without any serious side effects.
The magazine says that the problems associated with Covaxin included pain in the first place, then headaches and fever, fatigue. Speaking on the occasion, The Joining Director of Bharat Biotech, Suchitra Ella, said that Covaxin is the first vaccine in India whose data has been published in The Lancet. The Lancet article says that "the vaccine named BBV152 code was well tolerated in all the dose groups. There was also no serious vaccine-related incident."
The biotech industry information says that every vaccine complains of pain, but so far, there has been nothing in the Covaxin that requires treatment and is completely safe. The most condemned thing about Covaxin was that no data was public when it applied for emergency use permission. After his appearances in the Lancet, Suchitra Ella tweeted that "India's innovation has got international recognition.
Also Read:-
Elephant dies after resort workers throw burning tyre at it in Tamil Nadu, two arrested
Great opportunity for youngsters in Indian Air Force, Apply soon
Ram Mandir: Vishwa Sindhi Seva Sangam to donate 200 silver bricks